person · Reporting owner

Smith Julie

Disclosed activity across 4 companies

Tapewire entity: 40913
SEC CIK: 0001557928

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
EXELIXIS, INC.EXEL · Entity 3386	Director	May 27, 2026	May 29, 2026
Stoke Therapeutics, Inc.STOK · Entity 1723	Director	June 03, 2026	June 05, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

EXELIXIS, INC.

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	28,957	Reported balance After 2026-05-27 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 8,367 · Balance 28,957 F1: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date. F2: Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date.

F2: Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs.

Stoke Therapeutics, Inc.

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2036-06-02	Direct	17,786	Reported balance After 2026-06-03 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 17,786 · Balance 17,786 F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Audentes Therapeutics, Inc.

Report date January 15, 2020 · Filed January 15, 2020

Section 16 reporting ended · disclosed 2020-01-15. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.85 · Expires 2027-01-01	Direct	Reported balance After 2020-01-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-01-15 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.15 · Expires 2027-10-08	Direct	Reported balance After 2020-01-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-15 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.65 · Expires 2028-06-08	Direct	Reported balance After 2020-01-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-15 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.74 · Expires 2029-02-06	Direct	Reported balance After 2020-01-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-15 · Disposition to issuer · Disposed 16,200 · Balance 0 F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price.

F2: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration.

F3: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01.

Raptor Pharmaceutical Corp

Report date October 24, 2016 · Filed October 26, 2016

Section 16 reporting ended · disclosed 2016-10-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2016-10-25 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2016-10-24 · Other · Disposed 45,759 · Balance 64,179 F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Row 2 · 2016-10-25 · Disposition to issuer · Disposed 64,179 · Balance 0 F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.27 · Expires 2022-09-10	Direct	Reported balance After 2016-10-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-10-25 · Disposition to issuer · Disposed 152,050 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2024-07-29	Direct	Reported balance After 2016-10-25 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-10-25 · Disposition to issuer · Disposed 175,000 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2026-02-09	Direct	Reported balance After 2016-10-25 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-10-25 · Disposition to issuer · Disposed 240,595 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent.

F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.

F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 03, 2026 Filed Jun 5, 2026 20:31 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantDirector Stock Option (Right to Buy) · Derivative	17,786	$0.00 Strike: $29.46	$0.00	Disclosure SEC source: 0001557928-26-000002 · form4-06052026_080637.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,786 Underlying: Common Stock · 17,786 shares Expires 2036-06-02 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document
May 27, 2026 Filed May 29, 2026 21:43 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantCommon Stock	8,367	$0.00	$0.00	Disclosure SEC source: 0000939767-26-000080 · wk-form4_1780091013.xml · nonDerivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,957 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 27, 2027, subject to the Reporting Person's continuous service through that date. F2 · balance_after: Includes 8,367 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. Read SEC document
February 18, 2026 Filed Feb 20, 2026 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionOption (right to buy) · Derivative	20,030	$0.00 Strike: $21.69	$0.00	Disclosure SEC source: 0000939767-26-000029 · wk-form4_1771546714.xml · derivative · entry 9 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,030 shares Expires 2031-05-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 20,030 shares of Common Stock, became fully exercisable on May 31, 2024. Read SEC document
February 18, 2026 Filed Feb 20, 2026 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionOption (right to buy) · Derivative	44,087	$0.00 Strike: $19.39	$0.00	Disclosure SEC source: 0000939767-26-000029 · wk-form4_1771546714.xml · derivative · entry 8 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,087 shares Expires 2030-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 44,087 shares of Common Stock, became fully exercisable on June 1, 2023. Read SEC document
February 18, 2026 Filed Feb 20, 2026 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	SaleCommon Stock	20,030	$44.30	$887,329.00	Disclosure SEC source: 0000939767-26-000029 · wk-form4_1771546714.xml · nonDerivative · entry 6 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,590 F1 · balance_after: Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
February 18, 2026 Filed Feb 20, 2026 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionCommon Stock	20,030	$21.69	$434,450.70	Disclosure SEC source: 0000939767-26-000029 · wk-form4_1771546714.xml · nonDerivative · entry 5 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
February 18, 2026 Filed Feb 20, 2026 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	SaleCommon Stock	44,087	$44.50	$1,961,871.50	Disclosure SEC source: 0000939767-26-000029 · wk-form4_1771546714.xml · nonDerivative · entry 4 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,590 F1 · balance_after: Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
February 18, 2026 Filed Feb 20, 2026 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionCommon Stock	44,087	$19.39	$854,846.93	Disclosure SEC source: 0000939767-26-000029 · wk-form4_1771546714.xml · nonDerivative · entry 3 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
February 17, 2026 Filed Feb 20, 2026 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionOption (right to buy) · Derivative	42,422	$0.00 Strike: $18.19	$0.00	Disclosure SEC source: 0000939767-26-000029 · wk-form4_1771546714.xml · derivative · entry 7 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,422 shares Expires 2029-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 42,422 shares of Common Stock, became fully exercisable on May 26, 2022. Read SEC document
February 17, 2026 Filed Feb 20, 2026 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	SaleCommon Stock	42,422	$43.33	$1,838,145.26	Disclosure SEC source: 0000939767-26-000029 · wk-form4_1771546714.xml · nonDerivative · entry 2 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,590 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $44.30 to $44.44. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F1 · balance_after: Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
February 17, 2026 Filed Feb 20, 2026 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionCommon Stock	42,422	$18.19	$771,656.18	Disclosure SEC source: 0000939767-26-000029 · wk-form4_1771546714.xml · nonDerivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 9,812 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
June 03, 2025 Filed Jun 5, 2025 00:38 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantDirector Stock Option (Right to Buy) · Derivative	29,747	$0.00 Strike: $10.90	$0.00	Disclosure SEC source: 0001415889-25-015702 · form4-06052025_120602.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,747 Underlying: Common Stock · 29,747 shares Expires 2035-06-02 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 3, 2026 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document
May 29, 2025 Filed May 30, 2025 23:12 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantCommon Stock	9,812	$0.00	$0.00	Disclosure SEC source: 0000939767-25-000086 · wk-form4_1748646713.xml · nonDerivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,590 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock ("Common Stock"). The RSUs will vest as to 100% of the shares subject to the RSU award on May 29, 2026, subject to the Reporting Person's continuous service through that date. F2 · balance_after: Includes 19,827 shares of Common Stock that will be issued to the Reporting Person upon vesting of RSUs. Read SEC document
February 28, 2025 Filed Mar 1, 2025 01:35 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionOption (right to buy) · Derivative	19,294	$0.00 Strike: $19.77	$0.00	Disclosure SEC source: 0000939767-25-000045 · wk-form4_1740792942.xml · derivative · entry 8 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,294 shares Expires 2026-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 42,641 shares of Common Stock, became fully exercisable on May 23, 2019. Read SEC document
February 28, 2025 Filed Mar 1, 2025 01:35 UTC	EXELIXIS, INC. EXEL · Entity 3386	SaleCommon Stock	19,294	$37.62	$725,840.28	Disclosure SEC source: 0000939767-25-000045 · wk-form4_1740792942.xml · nonDerivative · entry 5 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,778 F1 · balance_after: Includes 10,015 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
February 28, 2025 Filed Mar 1, 2025 01:35 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionCommon Stock	19,294	$19.77	$381,442.38	Disclosure SEC source: 0000939767-25-000045 · wk-form4_1740792942.xml · nonDerivative · entry 4 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10,015 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
February 27, 2025 Filed Mar 1, 2025 01:35 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionOption (right to buy) · Derivative	23,347	$0.00 Strike: $19.77	$0.00	Disclosure SEC source: 0000939767-25-000045 · wk-form4_1740792942.xml · derivative · entry 7 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,294 Underlying: Common Stock · 23,347 shares Expires 2026-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 42,641 shares of Common Stock, became fully exercisable on May 23, 2019. Read SEC document
February 27, 2025 Filed Mar 1, 2025 01:35 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionOption (right to buy) · Derivative	31,167	$0.00 Strike: $20.50	$0.00	Disclosure SEC source: 0000939767-25-000045 · wk-form4_1740792942.xml · derivative · entry 6 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,167 shares Expires 2025-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 31,167 shares of Common Stock, became fully exercisable on May 24, 2018. Read SEC document
February 27, 2025 Filed Mar 1, 2025 01:35 UTC	EXELIXIS, INC. EXEL · Entity 3386	SaleCommon Stock	54,514	$38.13	$2,078,618.82	Disclosure SEC source: 0000939767-25-000045 · wk-form4_1740792942.xml · nonDerivative · entry 3 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,778 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $37.75 to $38.37. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. F1 · balance_after: Includes 10,015 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
February 27, 2025 Filed Mar 1, 2025 01:35 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionCommon Stock	23,347	$19.77	$461,570.19	Disclosure SEC source: 0000939767-25-000045 · wk-form4_1740792942.xml · nonDerivative · entry 2 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10,015 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
February 27, 2025 Filed Mar 1, 2025 01:35 UTC	EXELIXIS, INC. EXEL · Entity 3386	Exercise / conversionCommon Stock	31,167	$20.50	$638,923.50	Disclosure SEC source: 0000939767-25-000045 · wk-form4_1740792942.xml · nonDerivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,945 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 10,015 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Common Stock. Read SEC document
August 13, 2024 Filed Aug 16, 2024 00:18 UTC	EXELIXIS, INC. EXEL · Entity 3386	OtherCommon Stock	4,682	$0.00	$0.00	Disclosure SEC source: 0000939767-24-000129 · wk-form4_1723767514.xml · nonDerivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,778 F1 · shares: Reflects transfer of 4,682 shares to ex-spouse pursuant to a settlement agreement. F2 · balance_after: Includes 10,015 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:27 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantDirector Stock Option (Right to Buy) · Derivative	7,639	$0.00 Strike: $16.41	$0.00	Disclosure SEC source: 0001415889-24-015974 · form4-06072024_080629.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,639 Underlying: Common Stock · 7,639 shares Expires 2034-06-04 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document
May 31, 2024 Filed Jun 5, 2024 00:19 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantOption (right to buy) · Derivative	20,030	$0.00 Strike: $21.69	$0.00	Disclosure SEC source: 0000939767-24-000094 · wk-form4_1717546761.xml · derivative · entry 2 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,030 Underlying: Common Stock · 20,030 shares Expires 2031-05-30 F3 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the one-year anniversary of the Transaction Date, subject to the Reporting Person's continuous service through such date. Read SEC document
May 31, 2024 Filed Jun 5, 2024 00:19 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantCommon Stock	10,015	$0.00	$0.00	Disclosure SEC source: 0000939767-24-000094 · wk-form4_1717546761.xml · nonDerivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,460 F1 · date: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date. F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date. F2 · balance_after: Includes 10,015 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of RSUs. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock. Read SEC document
May 21, 2024 Filed May 23, 2024 22:55 UTC	EXELIXIS, INC. EXEL · Entity 3386	SaleCommon Stock	27,280	$21.12	$576,153.60	Disclosure SEC source: 0000939767-24-000077 · wk-form4_1716504931.xml · nonDerivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,445 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.11 to $21.17. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document
June 13, 2023 Filed Jun 15, 2023 22:26 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantDirector Stock Option (Right to Buy) · Derivative	19,441	$0.00 Strike: $12.46	$0.00	Disclosure SEC source: 0001209191-23-037537 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document
June 01, 2023 Filed Jun 3, 2023 01:10 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantOption (right to buy) · Derivative	44,087	$0.00 Strike: $19.39	$0.00	Disclosure SEC source: 0000939767-23-000055 · wk-form4_1685754626.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,087 Underlying: Common Stock · 44,087 shares Expires 2030-05-31 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document
June 07, 2022 Filed Jun 8, 2022 21:00 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantDirector Stock Option (Right to Buy) · Derivative	21,000	$0.00 Strike: $12.96	$0.00	Disclosure SEC source: 0001209191-22-035074 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The option shall vest on June 7, 2023 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document
May 26, 2022 Filed May 28, 2022 01:12 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantOption (right to buy) · Derivative	42,422	$0.00 Strike: $18.19	$0.00	Disclosure SEC source: 0000939767-22-000077 · wf-form4_165370034166320.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,422 Underlying: Common Stock · 42,422 shares Expires 2029-05-25 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document
June 08, 2021 Filed Jun 25, 2021 21:02 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantDirector Stock Option (Right to Buy) · Derivative	11,650	$0.00 Strike: $40.37	$0.00	Disclosure SEC source: 0001209191-21-043338 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,650 Underlying: Common Stock · 11,650 shares Expires 2031-06-07 F1 · derivative.exercise_date: The option shall fully vest on June 8, 2022 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document
May 27, 2021 Filed May 29, 2021 00:08 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantCommon Stock	16,424	$0.00	$0.00	Disclosure SEC source: 0000939767-21-000058 · wf-form4_162224691723172.xml · nonDerivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,725 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 27, 2022, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 16,424 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document
June 03, 2020 Filed Jun 5, 2020 21:31 UTC	Stoke Therapeutics, Inc. STOK · Entity 1723	GrantDirector Stock Option (Right to Buy) · Derivative	29,555	$0.00 Strike: $26.53	$0.00	Disclosure SEC source: 0001209191-20-034735 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,555 Underlying: Common Stock · 29,555 shares Expires 2020-06-02 F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares on September 3, 2020, and then 1/12th of the total shares vest quarterly thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document
May 21, 2020 Filed May 23, 2020 01:06 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantCommon Stock	15,538	$0.00	$0.00	Disclosure SEC source: 0000939767-20-000098 · wf-form4_159019595983746.xml · nonDerivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,301 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the shares subject to the restricted stock unit award on May 21, 2021, subject to the Reporting Person's continuous service through that date. F3 · balance_after: Includes 15,538 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:37 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	16,200	Not disclosed Strike: $24.74	Not disclosed	Disclosure SEC source: 0001209191-20-003436 · doc4.xml · derivative · entry 4 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,200 shares Expires 2029-02-06 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:37 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	10,000	Not disclosed Strike: $38.65	Not disclosed	Disclosure SEC source: 0001209191-20-003436 · doc4.xml · derivative · entry 3 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-08 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:37 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	9,000	Not disclosed Strike: $26.15	Not disclosed	Disclosure SEC source: 0001209191-20-003436 · doc4.xml · derivative · entry 2 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,000 shares Expires 2027-10-08 F3 · derivative.exercise_price: Reflects the correct exercise price of this option. The exercise price of this option was previously reported as $26.01. F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
January 15, 2020 Filed Jan 15, 2020 13:37 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	Disposition to issuerStock Option (Right to Buy) · Derivative	18,000	Not disclosed Strike: $17.85	Not disclosed	Disclosure SEC source: 0001209191-20-003436 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2027-01-01 F1 · kind: On December 2, 2019, Audentes Therapeutics, Inc. (the "Company") entered into an Agreement and Plan of Merger (as it may be amended, supplemented or otherwise modified from time to time, the "Merger Agreement") with Astellas Pharma Inc. ("Astellas") and Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas ("Merger Sub"), pursuant to which Astellas acquired the Company by a tender offer for all shares of Company common stock (the "Offer") and a subsequent merger (the "Merger"), each of which became effective on January 15, 2020. Pursuant to the Merger Agreement, (i) Merger Sub purchased all shares of Company common stock that were validly tendered pursuant to the Offer for a cash payment equal to $60.00 per share (the "Offer Price") and (ii) all shares of Company common stock outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were canceled and converted automatically into the right to receive the Offer Price. F2 · price: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, immediately prior to the Effective Time, all outstanding Company stock options, to the extent unvested, became fully vested, and at the Effective Time, each outstanding Company stock option was cancelled and converted into the right to receive an amount of cash (subject to any applicable withholding or other taxes required by applicable law) determined by multiplying (i) the number of shares of Company common stock subject to such stock option immediately prior to such cancellation by (ii) the excess, if any, of an amount in cash equal to the Offer Price, without any interest, over the exercise price per share of Company common stock subject to such stock option, less any applicable tax withholding. Any such option that had an exercise price that equaled or exceeded the Offer Price was cancelled for no consideration. Read SEC document
May 23, 2019 Filed May 25, 2019 00:47 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantOption (right to buy) · Derivative	42,641	$0.00 Strike: $19.77	$0.00	Disclosure SEC source: 0000939767-19-000136 · wf-form4_155874524378443.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,641 Underlying: Common Stock · 42,641 shares Expires 2026-05-22 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to the Reporting Person's continuous service through such date. Read SEC document
February 06, 2019 Filed Feb 8, 2019 17:28 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantStock Option (right to buy) · Derivative	16,200	$0.00 Strike: $24.74	$0.00	Disclosure SEC source: 0001209191-19-008676 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,200 Underlying: Common Stock · 16,200 shares Expires 2029-02-06 F1 · derivative.exercise_date: The option vests as to 100% of the shares upon the earlier of (i) the one-year anniversary of the grant date, and (ii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date. Read SEC document
June 08, 2018 Filed Jun 8, 2018 17:24 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $38.65	$0.00	Disclosure SEC source: 0001209191-18-036743 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The option vests as to 100% of the shares upon the earliest of (i) the Company's 2019 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date. Read SEC document
May 24, 2018 Filed May 25, 2018 00:30 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantOption (right to buy) · Derivative	31,167	$0.00 Strike: $20.50	$0.00	Disclosure SEC source: 0000939767-18-000110 · wf-form4_152720822079492.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,167 Underlying: Common Stock · 31,167 shares Expires 2025-05-23 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document
October 08, 2017 Filed Oct 10, 2017 18:07 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantStock Option (right to buy) · Derivative	9,000	$0.00 Strike: $26.01	$0.00	Disclosure SEC source: 0001209191-17-056532 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-10-08 F1 · derivative.exercise_date: The option vests as to 100% of the shares upon the earliest of (i) the Company's 2018 annual meeting of stockholders, (ii) the one-year anniversary of the grant date, and (iii) a Corporate Transaction of the Company as defined in the Company's 2016 Equity Incentive Plan; subject to the reporting person's continued service to the Company on the vesting date. Read SEC document
May 25, 2017 Filed May 27, 2017 00:53 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantOption (right to buy) · Derivative	23,491	$0.00 Strike: $19.57	$0.00	Disclosure SEC source: 0000939767-17-000117 · wf-form4_149584640178321.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,491 Underlying: Common Stock · 23,491 shares Expires 2024-05-24 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document
February 23, 2017 Filed Feb 25, 2017 02:00 UTC	EXELIXIS, INC. EXEL · Entity 3386	GrantOption (right to buy) · Derivative	16,620	$0.00 Strike: $21.74	$0.00	Disclosure SEC source: 0000939767-17-000014 · wf-form4_148798801033982.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,620 Underlying: Common Stock · 16,620 shares Expires 2024-02-22 F1 · derivative.exercise_date: Option granted pursuant to the 2014 Plan. Option will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document
January 01, 2017 Filed Jan 5, 2017 18:15 UTC	Audentes Therapeutics, Inc. BOLD · Entity 122788	GrantStock Option (right to buy) · Derivative	18,000	$0.00 Strike: $17.85	$0.00	Disclosure SEC source: 0001209191-17-002317 · doc4.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-01-01 F1 · derivative.exercise_date: The option vests as to 2.777% of the total shares monthly, beginning January 12, 2017, with 100% of the total shares vested and exercisable on December 12, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document
October 25, 2016 Filed Oct 26, 2016 16:38 UTC	Raptor Pharmaceutical Corp RPTP · Entity 181476	Disposition to issuerStock Option(right to buy) · Derivative	240,595	Not disclosed Strike: $3.74	Not disclosed	Disclosure SEC source: 0001140361-16-083647 · doc1.xml · derivative · entry 5 Smith Julie · CIK 0001557928 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 240,595 shares Expires 2026-02-09 F3 · price: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. Read SEC document
October 25, 2016 Filed Oct 26, 2016 16:38 UTC	Raptor Pharmaceutical Corp RPTP · Entity 181476	Disposition to issuerStock Option(right to buy) · Derivative	175,000	Not disclosed Strike: $8.13	Not disclosed	Disclosure SEC source: 0001140361-16-083647 · doc1.xml · derivative · entry 4 Smith Julie · CIK 0001557928 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 175,000 shares Expires 2024-07-29 F3 · price: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. Read SEC document
October 25, 2016 Filed Oct 26, 2016 16:38 UTC	Raptor Pharmaceutical Corp RPTP · Entity 181476	Disposition to issuerStock Option(right to buy) · Derivative	152,050	Not disclosed Strike: $5.27	Not disclosed	Disclosure SEC source: 0001140361-16-083647 · doc1.xml · derivative · entry 3 Smith Julie · CIK 0001557928 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152,050 shares Expires 2022-09-10 F3 · price: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. Read SEC document
October 25, 2016 Filed Oct 26, 2016 16:38 UTC	Raptor Pharmaceutical Corp RPTP · Entity 181476	Disposition to issuerCommon Stock	64,179	$9.00	$577,611.00	Disclosure SEC source: 0001140361-16-083647 · doc1.xml · nonDerivative · entry 2 Smith Julie · CIK 0001557928 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.